LIGAND PHARMACEUTICALS INC (LGND)

201.79 -0.76 (-0.38%)

As of 2026-03-03 12:02:55 EST

Ligand Pharmaceuticals is an American biopharmaceutical company that focuses on acquiring and developing royalty-generating assets. As of 2024, the company's portfolio included royalty rights to approximately 90 pharmaceutical products across a range of therapeutic areas. Notable products from which Ligand receives royalties include the multiple myeloma (cancer) treatments Kyprolis and Evomela, the kidney disease therapy Filspari, and the pneumococcal vaccine Vaxneuvance. The company also owns the drug development technology platform Captisol.

Traded asNasdaq: LGND
ISINUS53220K5048
CIK0000886163
LEI5493008K7TB0IKP37H79
EIN770160744
Sector—
IndustryPharmaceutical Preparations
CEOTodd C. Davis
Employees68
Fiscal Year End1231
Address3911 SORRENTO VALLEY BLVD, SAN DIEGO, CA, 92121
Phone858-550-7500
Websitehttp://ligand.com
Stock Quotes
trading_symbolregistrant_nametimepricechangepercentage_change
LGNDLIGAND PHARMACEUTICALS INC2026-03-03 12:02:55201.79-0.76-0.38
This is a preview of the latest data. Subscribe to access the full data.
Company Information
trading_symbolcentral_index_keyregistrant_nameisin_numberlei_numberein_numberexchangesic_codesic_descriptionfiscal_year_endstate_of_incorporationaddress_streetaddress_cityaddress_stateaddress_zip_codeaddress_countryaddress_country_codephone_numbermailing_addressbusiness_addressformer_nameindustryfounding_datechief_executive_officernumber_of_employeeswebsitemarket_capshares_issuedshares_outstandingdescriptionupdate_time
LGND0000886163LIGAND PHARMACEUTICALS INCUS53220K50485493008K7TB0IKP37H79770160744Nasdaq2834Pharmaceutical Preparations1231DE3911 SORRENTO VALLEY BLVDSAN DIEGOCA92121UNITED STATESUS858-550-75003911 SORRENTO VALLEY BLVD, SAN DIEGO, CA, 921213911 SORRENTO VALLEY BLVD, SAN DIEGO, CA, 92121LIGAND PHARMACEUTICALS—1987Todd C. Davis68http://ligand.com1,100,000,00019,656,00019,681,720Ligand Pharmaceuticals is an American biopharmaceutical company that focuses on acquiring and developing royalty-generating assets. As of 2024, the company's portfolio included royalty rights to approximately 90 pharmaceutical products across a range of therapeutic areas. Notable products from which Ligand receives royalties include the multiple myeloma (cancer) treatments Kyprolis and Evomela, the kidney disease therapy Filspari, and the pneumococcal vaccine Vaxneuvance. The company also owns the drug development technology platform Captisol.2026-02-26 16:56:47
This is a preview of the latest data. Subscribe to access the full data.
LGND Stock Price (End-of-Day)
This is a preview of the latest data. Subscribe to access the full data.
LGND Stock Price (1-Minute)
This is a preview of the latest data. Subscribe to access the full data.
Market Cap
Fiscal YearMarket CapChange In Market CapPercentage Change In Market CapShares OutstandingChange In Shares OutstandingPercentage Change In Shares Outstanding
20241,100,000,000200,000,00022.222219,255,3531,550,0668.7548
2023900,000,000-100,000,000-1017,705,287628,6293.6812
20221,000,000,000-800,000,000-44.444417,076,658224,0081.3292
This is a preview of the latest data. Subscribe to access the full data.
Executive Compensation
Executive NameExecutive PositionFiscal YearSalaryBonusStock AwardsIncentive Plan CompensationOther CompensationTotal Compensation
Andrew ReardonChief Legal Officer, Secretary2024451,950—1,428,806240,0007,3803,270,956
Matthew KorenbergChief Operating Officer, President2024385,545—6,716,643142,789118,32613,165,669
Todd C. DavisChief Executive Officer2024695,834—6,429,536637,0009,96012,914,980
Tavo EspinozaChief Financial Officer2024469,550—1,428,806250,0007,3803,298,556
Andrew ReardonChief Legal Officer, Secretary2023434,262—1,126,169173,7056,9002,337,081
This is a preview of the latest data. Subscribe to access the full data.
Employee Count
Fiscal YearEmployee Count
202547
202468
202358
This is a preview of the latest data. Subscribe to access the full data.
Income Statements
Fiscal Year202520242023
Revenue268,087,000167,133,000131,314,000
Cost Of Revenue———
Gross Profit———
Research And Development Expenses81,182,00021,425,00024,537,000
General And Administrative Expenses92,449,00078,654,00052,790,000
Operating Expenses———
Operating Income41,002,000-22,606,00011,942,000
Net Income124,453,000-4,032,00052,154,000
Earnings Per Share Basic6.44-0.223.02
Earnings Per Share Diluted6.13-0.222.94
Weighted Average Shares Outstanding Basic19,338,00018,290,00017,298,000
Weighted Average Shares Outstanding Diluted20,294,00018,290,00017,757,000
This is a preview of the latest data. Subscribe to access the full data.
Balance Sheet Statements
Fiscal Year202520242023
Cash And Cash Equivalents174,927,00072,307,00022,954,000
Marketable Securities Current558,594,000183,858,000147,355,000
Accounts Receivable59,601,00038,376,00032,917,000
Inventories9,126,00014,114,00023,969,000
Non Trade Receivables1,446,0004,073,0006,395,000
Other Assets Current5,785,00016,897,0002,657,000
Total Assets Current832,271,000331,559,000237,429,000
Marketable Securities Non Current———
Property Plant And Equipment3,571,00015,133,00015,607,000
Other Assets Non Current12,582,0006,924,0005,923,000
Total Assets Non Current728,366,000610,215,000549,787,000
Total Assets1,560,637,000941,774,000787,216,000
Accounts Payable3,238,0005,233,0002,427,000
Deferred Revenue621,0001,278,0001,222,000
Short Term Debt———
Other Liabilities Current135,00027,906,00012,467,000
Total Liabilities Current37,447,00037,112,00016,782,000
Long Term Debt446,192,000——
Other Liabilities Non Current16,629,00030,163,00027,758,000
Total Liabilities Non Current505,978,00074,223,00069,521,000
Total Liabilities543,425,000111,335,00086,303,000
Common Stock20,00020,00018,000
Retained Earnings608,088,000498,984,000503,016,000
Accumulated Other Comprehensive Income8,455,000-5,942,000-817,000
Total Shareholders Equity1,017,212,000830,439,000700,913,000
This is a preview of the latest data. Subscribe to access the full data.
Cash Flow Statements
Fiscal Year202520242023
Depreciation And Amortization33,775,00035,239,00036,521,000
Share Based Compensation Expense46,849,00041,089,00025,743,000
Other Non Cash Income Expense1,022,000-20,010,000250,000
Change In Accounts Receivable21,737,0006,459,0002,601,000
Change In Inventories-4,988,000-9,619,00010,870,000
Change In Non Trade Receivables-2,667,000-2,310,0001,781,000
Change In Other Assets———
Change In Accounts Payable5,882,00013,903,000-4,704,000
Change In Other Liabilities3,887,000-1,291,0009,865,000
Cash From Operating Activities49,359,00097,047,00049,577,000
Purchases Of Marketable Securities726,713,000226,384,000126,764,000
Sales Of Marketable Securities159,584,000229,367,000148,765,000
Acquisition Of Property Plant And Equipment452,0001,821,0003,521,000
Acquisition Of Business0010,405,000
Other Investing Activities—00
Cash From Investing Activities-377,322,000-143,664,000-11,682,000
Tax Withholding For Share Based Compensation9,599,0005,136,0004,547,000
Payments Of Dividends———
Issuance Of Common Stock037,140,000—
Repurchase Of Common Stock15,000,00000
Issuance Of Long Term Debt———
Repayment Of Long Term Debt0076,854,000
Other Financing Activities47,100,00065,200,00022,200,000
Cash From Financing Activities428,223,00097,141,000-59,947,000
Change In Cash102,620,00049,353,000-22,052,000
Cash At End Of Period174,927,00072,307,00022,954,000
Income Taxes Paid7,802,00019,206,0008,770,000
Interest Paid321,000263,000288,000
This is a preview of the latest data. Subscribe to access the full data.
Key Metrics
Fiscal Year202520242023
Earnings Per Share6.44-0.223.02
Price To Earnings Ratio29.3587-487.045523.649
Earnings Growth Rate-3,027.2727-107.2848-252.5253
Price Earnings To Growth Ratio-0.00974.5397-0.0937
Book Value Per Share52.601745.40440.5199
Price To Book Ratio3.59442.35991.7626
Ebitda170,745,00053,450,00098,101,000
Enterprise Value3,927,500,660——
Dividend Yield———
Dividend Payout Ratio———
Debt To Equity Ratio0.4386——
Capital Expenditures22,213,00034,765,00039,646,000
Free Cash Flow27,146,00062,282,0009,931,000
Return On Equity0.1223-0.00490.0744
One Year Beta0.85021.34660.8633
Three Year Beta0.95881.17871.133
Five Year Beta1.08181.12131.1343
This is a preview of the latest data. Subscribe to access the full data.
Insider Transactions
Insider NameRelationship To IssuerTransaction DateAmount Of SecuritiesAcquired Or DisposedSecurities Owned Following Transaction
Davis Todd CDirector, Chief Executive Officer2026-02-152,039D195,946
Davis Todd CDirector, Chief Executive Officer2026-02-154,255D191,691
Davis Todd CDirector, Chief Executive Officer2026-02-152,805D188,886
Espinoza OctavioChief Financial Officer2026-02-151,026D35,505
Espinoza OctavioChief Financial Officer2026-02-151,223D34,282
This is a preview of the latest data. Subscribe to access the full data.
House Trading
Name Of Reporting PersonReport DateStateTransaction TypeTransaction DateOwner TypeAmount
Gilbert Cisneros2026-02-13CA31Purchase2026-01-15—$1,001 - $15,000
Gilbert Cisneros2026-02-13CA31Purchase2026-01-05—$1,001 - $15,000
Lamar Smith2018-01-09TX21Purchase2017-12-01—$1,001 - $15,000
This is a preview of the latest data. Subscribe to access the full data.
Institutional Holdings
Investor NamePeriod Of ReportMarket ValueAmount Of SecuritiesPrice Per Security
GROUP ONE TRADING LLC2025-12-31558,3242,953189.0701
PICTON MAHONEY ASSET MANAGEMENT2025-12-312,08011189.0909
Ameritas Investment Partners, Inc.2025-12-31301,3781,594189.0703
ZIONS BANCORPORATION, NATIONAL ASSOCIATION /UT/2025-12-315673189
Janney Capital Management LLC2025-12-31452,0002,393188.8842
This is a preview of the latest data. Subscribe to access the full data.
Mutual Fund Holdings
Registrant NamePeriod Of ReportFund NameFund SymbolAmount Of UnitsValue In UsdPercentage Value Compared To Assets
RYDEX SERIES FUNDS2025-12-31Class CRYCMX275,104.890.0605
RYDEX SERIES FUNDS2025-12-31Class ARYAKX275,104.890.0605
RYDEX SERIES FUNDS2025-12-31Class HRYMKX275,104.890.0605
RYDEX DYNAMIC FUNDS2025-12-31H-Class SharesRYRSX9718,339.790.0336
RYDEX DYNAMIC FUNDS2025-12-31C-Class SharesRYRLX9718,339.790.0336
This is a preview of the latest data. Subscribe to access the full data.